Teva's anti-IL-15 antibody meets primary endpoint in phase 2a celiac disease trial

Teva Pharmaceuticals reported that its anti‑interleukin‑15 antibody, TEV‑408, achieved the primary endpoint in a phase 2a study of 50 adults with celiac disease. Participants received a single dose of the drug or placebo and then consumed gluten daily for six weeks, with TEV‑408 markedly reducing intestinal damage compared with placebo.

The company’s chief medical officer highlighted that the data suggest the IL‑15 pathway can be targeted to address the underlying immune injury in celiac disease, moving beyond merely managing gluten exposure.

No safety concerns were identified in the trial, and Teva said additional dose‑ranging work and deeper analysis of the phase 2 data are required before planning a phase 3 study. The timeline for further development will depend on clinical outcomes and regulatory alignment.